Comment from Association for Accessible Medicines

Summary: The Association for Accessible Medicines (AAM) supports the modernization of the M4Q(R2) draft guidance but requests a long transition period of at least five years to manage the operational impact on generic and biosimilar manufacturers. They also advocate for the guidance to be applied prospectively rather than retroactively and request further clarification to avoid information duplication within the new framework.